Accurate assessment of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) patients after initial chemotherapy is essential to evaluate the efficacy of therapeutic regimens. Wilms tumor 1 (WT1) is a pan-leukemic marker used for identification of the leukemic clone rather than the use of individual specific molecular aberration of ALL.
Methods
Using a real-time quantitative polymerase chain reaction, bone marrow samples from 41 newly diagnosed Egyptian ALL patients; 22 adults and 19 children were examined for WT1 expression. After induction therapy, WT1 expression was reestimated in 20 ALL patients.
Results
WT1 was overexpressed in adult and pediatric ALL patients (95.4% and 89.4%, respectively). WT1 expression at diagnosis had no statistically significant impact on disease-free survival of patients (P = 0.054). However, WT1 expression increased after induction chemotherapy in the 3 pediatric patients who had relapse.
Conclusions
WT1 is a leukemia-associated molecular marker that may be used for the diagnosis and for monitoring clinical progress in ALL; it also can be used as a molecular target for adoptive immunotherapy.
HeeschS, GoekbugetN, StrouxA. Prognostic implication of mutations and expression of Wilms tumor (WT1 gene) in adult acute T-lymphoblastic leukemia. Heamatologica. 2010; 95: 942–949.
2.
SpanakiA, LinardakisE., PerdikogianniC. Quantitative assessment of WT1 expression in diagnosis of childhood acute leukemia. Leuk Res. 2007; 31: 570–572.
3.
SugiyamaH.Wilms’ tumor gene WT1 as a tumor marker for leukemic blast cells and its role in leukemogenesis. Methods Mol Med. 2002; 68: 223–237.
4.
WagnerKD, WagnerN, SchedlA.The complex life of WT1. J Cell Sci. 2003; 116: 1653–1658.
5.
LeeSB, HaberDA.Wilms tumor and the WT1 gene. Exp Cell Res. 2001; 10: 74–99.
6.
BoublikovaL, KalinovaM, RyanJ. Wilms’ tumor gene 1 (WT1) expression in childhood acute lymphoblastic leukemia: a wide range of WT1 expression levels, its impact on prognosis and minimal residual disease monitoring. Leukemia. 2006; 20: 254–263.
7.
HosenN, SonodaY, OjiY. Very low frequencies of human normal CD34+ haematopoietic progenitor cells express the Wilms’ tumour gene WT1 at levels similar to those in leukemia cells. Br J Haematol. 2002; 116: 409–420.
8.
LoebDM, SummersJL, BurwellEA. An isoform of the Wilms’ tumor suppressor gene potentiates granulocytic differentiation. Leukemia. 2003; 17: 965–971.
9.
SummersK, StevensJ, KakkasI. Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia. 2007; 21: 550–551.
10.
CilloniD, GottardiE, De-MicheliD. Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients. Leukemia. 2002; 16: 2115–2121.
11.
KerstG, BergoldN, GiesekeF. WT1 protein expression in childhood acute leukemia. Am J Hematol. 2008; 83: 382–386.
12.
De GreefG, VanW, BoogartsM.Criteria for defining a complete remission in acute myeloid leukemia. Br J Haematol. 2005; 128: 184–191.
13.
LapillonneH, RennevilleA, AuvrignonA. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006; 24: 1507–1515.
14.
MeshinchiS, ArceciJR.Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia. Oncologist. 2007; 12: 341–355.
15.
MiwaH, BeranM, SaundersGF.Expression of the Wilms tumor gene (WT1) in human leukemias. Leukemia. 1992; 6: 405–409.
16.
ChiusaL, Francia di CelleP, CampisiP. Prognostic value of quantitative analysis of WT1 gene transcripts in adult acute lymphoblastic leukemia. Haematologica. 2006; 91: 270–271.
17.
ChenZ.The possible role and application of WT1 in human leukemia. Int J Hematol. 2001; 73: 39–46.
18.
ChenJS, HsiaoCC, SheenJM. Comparison of minimal residual disease (MRD) estimated by flowcytometry and by real time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia. Leuk Res. 2007; 31: 1351–1357.
19.
MenssenHD, RenkHJ, RodeckU. Presence of Wilms tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia. 1995; 9: 1060–1067.
GaigerA, CarterL, GreinixH. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res. 2001; 7: 761s–765s.
23.
GargM, MooreH, TobalK. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukemia. Br J Haematol. 2003; 123: 49–59.
24.
MagyarosyE, VargaN, TimarJ. Follow up of minimal residual disease in acute childhood lymphoblastic leukemia by WT1 gene expression in the peripheral blood: the Hungarian experience. Pediatr Hematol Oncol. 2003; 20: 65–74.
25.
ImashukuS, TeruiK, MatsuyamaT. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan. Bone Marrow Transplant. 2003; 31: 1127–1135.
26.
InoueK, SugiyamaH, OgawaH. WT1as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994; 84: 3071–3079.
27.
CilloniD, SaglioG.WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome. Acta Heamatolo. 2004; 112: 79–84.
28.
KangLim C, GohYT, HwangWYK. Studies of Wilms tumor gene (WT1) expression in adult acute leukemias in Singapore. Biomark Insights. 2007; 2: 293–298.
29.
WangJ, OueT, UeharaS. The role of WT1 gene in neuroblastoma. J Pediatr Surg. 2011; 46: 326–331.
30.
StaussHJ, ThomasS, Cesco-GaspereM. WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells. Blood Cells Mol Dis. 2008; 40: 113–116.
31.
OkaY, TsuboiA, OjiY. WT1 peptide vaccine for the treatment of cancer. Curr Opin Immunol. 2008; 20: 211–220.
